MarsBars/E+ via Getty Images
- FibroGen (NASDAQ:FGEN) said late Friday that its chief financial officer and chief medical officer will both be leaving the company due to budget cuts.
- The company said CFO Juan Graham will stay with the company until Dec. 15, while CMO Dr. Deyaa Adib will leave on Nov. 1. Both were informed of their terminations on Aug. 30, according to an SEC filing.
- FibroGen (FGEN) announced in late July that it was slashing its U.S. workforce by 75% due to disappointing clinical results for its pancreatic cancer drug candidate pamrevlumab.
- Shares of FibroGen (FGEN) closed 8% lower on Friday.
